Abstract
The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A, oral polio vaccine, and smallpox proved to be reliable approaches for immunization for prolonged periods. During the pandemic, we produced an inactivated SARS-CoV-2 vaccine candidate, having the advantages of being manufactured rapidly and tested easily in comparison with recombinant vaccines. In this study, an inactivated virus vaccine that includes a gamma irradiation process for the inactivation as an alternative to classical chemical inactivation methods so that there is no extra purification required has been optimized. The vaccine candidate (OZG-38.61.3) was then applied in mice by employing the intradermal route, which decreased the requirement of a higher concentration of inactivated virus for proper immunization, unlike most of the classical inactivated vaccine treatments. Hence, the novelty of our vaccine candidate (OZG-38.61.3) is that it is a non-adjuvant added, gamma-irradiated, and intradermally applied inactive viral vaccine. Efficiency and safety dose (either 1013 or 1014 viral copy per dose) of OZG-38.61.3 was initially determined in Balb/c mice. This was followed by testing the immunogenicity and protective efficacy of OZG-38.61.3. Human ACE2-encoding transgenic mice were immunized and then infected with a dose of infective SARS-CoV-2 virus for the challenge test. Findings of this study show that vaccinated mice have lower SARS-CoV-2 viral copy number in oropharyngeal specimens along with humoral and cellular immune responses against the SARS-CoV-2, including the neutralizing antibodies similar to those shown in Balb/c mice without substantial toxicity. Subsequently, plans are being made for the commencement of Phase 1 clinical trial of the OZG-38.61.3 vaccine for the COVID-19 pandemic.
Competing Interest Statement
C.T., D.D.K., B.Y., G.S.K., S.D., Dilek Telci, and F.S. are inventors of patent applications (pending) including -A Method For The Production Of Fast, Inclusive And High-Dose Inactive Vaccine For Use Against SARS-CoV-2 Virus- (2020/13279) and -A Fast, Inclusive And High-Dose Inactive Method For Adjuvant Positive Vaccination To Be Used Against SARS-CoV-2 Virus- (2020/14033) at Turkish Patent and Trademark Office. No other author has a competing interest except for these authors.
Footnotes
↵# These authors equally contributed to this study.
* Acknowledgment: Sevda Demir and Sezer Akyoney are funded by TUBITAK 2247-C Trainee Researcher Scholarship Program (STAR). Selen Abanuz and Ilayda Sahin are supported by TUBITAK-BIDEB 2244-University-Industry PhD program, project number 118C082.
† Conflict of interest: C.T., D.D.K., B.Y., G.S.K., S.D., Dilek Telci, and F.S. are inventors of patent applications (pending) including “A Method For The Production Of Fast, Inclusive And High-Dose Inactive Vaccine For Use Against SARS-CoV-2 Virus” (2020/13279) and “A Fast, Inclusive And High-Dose Inactive Method For Adjuvant Positive Vaccination To Be Used Against SARS-CoV-2 Virus” (2020/14033) at Turkish Patent and Trademark Office. No other author has a competing interest except for these authors.
‡ Funding statement: All funding in the work was supported by Acibadem Healthcare Group.
A mistaken word was changed from "disseminated" to "reduced" through the manuscript in the sentence "Thus, viral load analyses in the oropharyngeal specimens showed that the SARS-CoV-2 infection was significantly reduced in the vaccinated groups." In addition, Fig 2a, 2b and 2c were forgotten to be added into the manuscript.